On Friday, October 13, 2023, our Managing Director Ms. Jennifer Che participated as a panelist in InvestHK’s event “Unlock the Life & Health Sciences Potential through Innovation”. Keynote speeches focused on Hong Kong’s strengths in the life sciences (good medical schools, strong research) and also Hong Kong’s challenges bridging the gap between fundamental research and commercial products. The panel discussion centered around “Hong Kong as a life and health technology innovation hub.” Moderated by Dr. Josephine Au from InvestHK, the other panel members included Ir. Eric Chan from Hong Kong Cyberport Management Co. Ltd., Dr. Grace Lau from HKSTP Institute of Translational Research, Ms. Simone Song from ORI Capital and Mr. Henry Yau from HKU Clinical Trials Centre. Jennifer shared about Hong Kong’s uniqueness as a place to find IP experts having international qualifications as well as cross-border experience. She also expressed frustration at how many HK companies still don’t value the importance of good IP strategy (and are unwilling to invest in such matters), which hurts them when they enter the international stage down the road. It was an enlightening discussion and valuable to hear various people’s thoughts on the future of Hong Kong in the life & health sciences area.
我們過去活動
Recommended Insights
Diagnostic Claims in China
2020年1月9日The Chinese Patent Law excludes patenting methods of diagnosing or treating a disease. More specifically, this refers to processes of identifying, determining, or eliminating the cause or focus of diseases which are practiced directly on living human or animal bodies. Please keep in mind that instruments used for implementing these methods are still patentable. So […]
閱讀更多 >
China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)
2021年4月30日This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
閱讀更多 >
First Ever Successful Invalidation Challenge Due to Unauthorized Foreign Filing
2023年3月8日What does an invention “completed” in China mean? China and the US are similar in that both countries highly value national security, and thus have rules regulating the exportation of technology and information from within their borders. This includes new inventions that arise from within their respective borders. As such, both governments require inventors who […]
閱讀更多 >
Narrow Claim Scope of a Chinese Utility Model Patent Fuels Design-Arounds by Failing to Curb Competing Products:
2020年10月28日Learning from a 2019 China’s Top 50 Representative IP Case The number of patent applications in China is now the highest in the world, with more than half the applications filed as utility model applications (UMs). For example, there were more than 2 million UMs filed in 2018 alone (for the difference between a utility […]
閱讀更多 >